Goldman Sachs Group Inc Neu Base Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.41 - $1.3 $122 - $390	-300 Reduced 0.36%	82,199 $32,000
Q3 2022 Nov 10, 2022	SELL	$0.41 - $1.3 $122 - $390	-300 Reduced 0.36%	82,199 $0
Q2 2022 May 14, 2024	BUY	$0.82 - $1.93 $67,649 - $159,223	82,499 New	82,499 $87,000
Q2 2022 Aug 15, 2022	BUY	$0.82 - $1.93 $245 - $579	300 Added 0.36%	82,499 $87,000
Q1 2022 May 16, 2022	SELL	$1.26 - $2.95 $241 - $566	-192 Reduced 0.23%	82,199 $155,000

Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $58,253 - $93,652	-22,405 Reduced 21.38%	82,391 $232,000
Q3 2021 Nov 10, 2021	BUY	$3.27 - $4.76 $342,682 - $498,828	104,796 New	104,796 $378,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.